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ABSTRACT 
Diabetes mellitus is a complex metabolic disorder that leads to various micro-vascular complications. The present 
study elucidated the effect of chloroform extract of leaves of Ficus glomerata (CHFG) in streptozotocin-induced 
early diabetic renal and neural complications. Wistar rats were injected with STZ (55 mg/kg, i.p.) to produce 
experimental diabetes. Two weeks after the stabilization of diabetes, CHFG extract at the dose of 200 and 400 
mg/kg (CHFG 200 and CHFG 400) and metformin at the dose of 250 mg/kg (Met 250) was administered to the 
diabetic rats for further two weeks. Diabetic rats showed an increase in blood glucose, plasma urea, uric acid, 
creatinine, triglyceride, and total cholesterol level. The change in behavioral parameters such as thermal hyperal-
gesia and cold allodynia with compromised sciatic nerve and kidney antioxidant status were seen in diabetic rats. 
Diabetic rats treated with CHFG 200, CHFG 400, and Met 250 showed a decrease in blood glucose, plasma urea, 
uric acid, creatinine, triglyceride, and total cholesterol level. Also, it improved altered behavioral parameters such 
as thermal hyperalgesia and cold allodynia. It also restored the sciatic nerve and kidney antioxidant status. The 
results of kidney and sciatic nerves histopathological study were in line with the results of biochemical parameters 
that confirmed the favorable role of CHFG. Characterization of CHFG by LC-MS revealed the presence of diverse 
phytoconstituents, which might be responsible for its protective effect. 
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INTRODUCTION 
Diabetes mellitus (DM) is a complicated 
disorder caused by genetic or environmental 
factors (Bronwyn et al., 1995; Fatemeh et al., 
2009; Todd et al., 1987). It is one of the most 
common endocrine diseases with its global 
prevalence of 9.3 % of the world population 
and is predicted to rise to 10.2 % by 2030 and  
 
 
10.9 % by 2045 (International Diabetes Fed-
eration, 2019). All forms of diabetes are char-
acterized by chronic hyperglycemia and the 
development of diabetes-specific microvas-
cular complications (Ohtsuji et al., 2008). As 
a result of this, diabetes is one of the major 
cause of neuropathic pain, end-stage renal 
disease, and cardiovascular diseases.  
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Chronic hyperglycemia stimulates the 
polyol pathway, causing osmotic stress, in-
creases the generation of reactive oxygen spe-
cies, which leads to oxidative stress in the tis-
sues. An increasing body of data supports the 
role of oxidative stress in the pathogenesis of 
diabetic microvascular complications (Ah-
mad et al., 2015; Bashan et al., 2009; 
Mahmood and Neaimy, 2008; Nishikawa et 
al., 2000). There are many drugs to treat dia-
betes, but none have been successful for the 
treatments of its complications completely. 
Therefore its treatment remained as one of the 
challenge faced by modern medicine. Hyper-
glycemic control remains a primary therapeu-
tic target when dealing with diabetic compli-
cations in both types of diabetes (Mahmood 
and Neaimy, 2008; Sima and Kamiya, 2006). 
A significant benefit of the use of phytocon-
stituents, minerals, and vitamins is thought to 
be due to its capability to scavenge free radi-
cals and thus lowering the incidence of dia-
betic complications (Pirat, 1977; Dal and Si-
grist, 2016). Plants are always a good source 
of active pharmacological agents, and many 
of the currently available therapeutic agents 
have been derived from them (Patel et al., 
2012). Many biologically active compounds 
from plant sources such as phenolics, flavo-
noids, lycopene, saponins, triterpenoids, and 
many others have the antidiabetic effect 
(Grover et al., 2002). Traditional, comple-
mentary, and alternative medicines are in-
creasingly used for the treatment of diabetes 
and its complications (Dodda and Ciddi, 
2014; Snehal et al., 2017; Dal and Sigrist, 
2016).  
Various medicinal plants, especially those 
belonging to the genus Ficus and its phyto-
constituents, have been used for the treatment 
of diabetes and related chronic complications 
since ancient times (Deepa et al., 2018). Ficus 
glomerata (FG), family Moraceae is well 
known as a Cluster fig tree, Goolar, Indian fig 
tree, Umber, Udumbara, Rumadi, Dimri, Blue 
lotus found in the Indian subcontinent, Indo-
China, Australia and Malaysia (Joy et al., 
2001; Kunwar and Bussmann, 2006). All 
parts of FG are medicinally important and 
used widely in the treatment of jaundice, 
wound healing, dysentery, diabetes, biliary 
disorders and inflammatory conditions (Nad-
karni, 1976; Patil et al., 2009; Satish et al., 
2014). Our previous study revealed the in 
vitro antidiabetic and antioxidant activity of 
CHFG (Abusufyan et al., 2018). However, 
there is no in vivo data about the efficacy of 
this extract available in diabetic renal and 
neural complications. Based on this, CHFG 
was selected to investigate its effect on early 
diabetic renal and neural complications. 
 
METHODS AND MATERIALS 
Chemicals reagents 
A free sample of metformin procured 
from USV Pvt Ltd, Mumbai. Streptozotocin 
was purchased from Sisco Research Labora-
tories Pvt. Ltd, Mumbai. All other chemicals 
were of analytical grade and obtained from 
commercial sources. 
 
Preparation and selection of FG leaf  
extract 
The leaves of FG were collected from the 
Sindhudurg district of Maharashtra, India, 
and identified with authentication no. 15-023 
by botanist Dr. A. S. Upadhye of Agharkar 
Research Institute, Pune, India. The powdered 
leaf material was extracted by successive sol-
vent extraction with the solvents of increasing 
order of polarity and concentrated by using a 
rotary evaporator. Based on our previous 
study, chloroform extract (CHFG) was se-
lected for the final investigation as it showed 
maximum antidiabetic and considerable anti-
oxidant activity (Abusufyan et al., 2018). 
 
CHFG extract analysis 
The preliminary phytochemical estima-
tion of the extracts was studied by the stand-
ard method of Khandelwal (2013). The HR-
LCMS of the selected extract was carried out 
at the Sophisticated Analytical Instrument Fa-
cility (SAIF) of IIT Bombay, Pawai, Mumbai, 
by using Agilent high-resolution liquid chro-
matography and mass spectrometry model- 
G6550A with 0.01 % mass resolution. The 
electrospray ion source was used to operate 
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the MS system. Solvents used were 100 % of 
water (A) and 100 % of acetonitrile (B). The 
elution started with a linear gradient; within 
30 minutes of acquisition time, the initial 2 
minutes, the flow of solvent composition A: 
B was 95:5. The injection volume was 3 µl, 
and the flow rate was 0.2 ml min-1. The MS 
signals were used for qualitative analysis 
based on specific mass spectra. The chroma-
tographic data were analyzed by using the 
software from Agilent, USA. For the detec-
tion of compounds, the MS spectra of the an-
alyzed samples were compared with the spec-
tra from the library.  
 
Acute oral toxicity test  
Acute oral toxicity test was conducted as 
per the OECD guideline No. 423. A single 
oral dose of 2000 mg/kg of CHFG was admin-
istered to overnight fasting Wistar albino rats. 
The sign and symptoms of toxicity were ob-
served in the animals for 24 hours. The mor-
tality, if any, was noted for two weeks. 
 
Oral glucose tolerance test (OGTT) and  
selection of dose 
Doses equivalent to 200, 400, and 600 
mg/kg of CHFG extract were calculated and 
suspended in 1 % v/v of tween 80 solutions. 
OGTT was carried out on overnight fasting 
normal rats. 1 % v/v of tween 80, CHFG (200, 
400, and 600 mg/kg) and metformin (250 
mg/kg) were administered to five groups of 
rats, respectively. Glucose (2 g/kg) was fed 30 
min after pre-treatment with 1 % v/v of tween 
80, CHFG, and metformin. Blood glucose 
levels were observed at 0, 30, 60, 120, and 
240 min after glucose load to assess the effect 
of the extract. Two doses with optimum dose-
dependent anti-hyperglycemic activity 
against glucose tolerance in normal rats were 
selected for the final study in STZ induced di-
abetic rats. 
 
Animal’s treatments and experimental  
design 
Healthy male Wistar albino rats weighing 
300-350 g were procured from the National 
Institute of Biosciences, Pune, Maharashtra, 
India, and housed in polypropylene cages at 
the temperature of 22 ± 1 °C and relative hu-
midity of 50 to 60 % with a 12 h light/dark 
cycle. The animal experiments were approved 
by the Institutional Animal Ethics Committee 
(IAEC), School of Pharmacy-AIKTC, New 
Panvel (Approval No. AIKTC/SoP/IAEC/ 
Approval/2016/1). Standard pellet diet and 
water ad libitum were provided to the experi-
mental animals throughout the experiment. 
Diabetes was induced by a single injection of 
streptozotocin (STZ, 55 mg/kg, i.p.) freshly 
prepared in 0.1 M citrate buffer pH 4.5) in rats 
(Azahar et al., 2012). Blood glucose level was 
measured, and rats with blood glucose levels 
above 250 mg/dl were considered diabetic. 
Two weeks post-STZ injection diabetic rats 
with stable blood glucose level were divided 
into different groups as follow: 
Group I: Normal control (n = 6), normal rats 
treated with 10 ml/kg, p.o. of distilled water. 
Group II: Diabetic control (n = 6), STZ in-
duced diabetic rats treated with vehicle (1 % 
v/v of tween 80 in distilled water 10 ml/kg, 
p.o.). 
Group III: STZ + Met 250 (n = 6), STZ in-
duced diabetic rats treated with Metformin 
250 mg/kg.  
Group IV: STZ + CHFG 200 (n = 6), STZ in-
duced diabetic rats treated with CHFG 200 
mg/kg.  
Group V: STZ + CHFG 400 (n = 6), STZ in-
duced diabetic rats treated with CHFG 400 
mg/kg. 
All the treatments were administered 
daily via a standard orogastric cannula for two 
weeks. The changes in the blood glucose 
level, body weight, thermal hyperalgesia, and 
cold allodynia were observed after one and 
two weeks post-treatment. At the end of the 
treatment, 12 hours fasted rats were eu-
thanized, and blood samples were collected 
by the retro-orbital plexus. The blood samples 
were centrifuged at 1300 g for separation of 
serum and used for estimation of serum urea, 
uric acid, creatinine, triglycerides, and total 
cholesterol level. Kidneys and sciatic nerves 
were isolated from euthanized animals, rinsed 
with ice-cold saline, and used for estimation 
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of tissue antioxidant status and histopatholog-
ical study. 
 
Measurements of fasting blood glucose  
The fasting blood glucose was measured 
to study the effect of pre-treatment, one and 
two-week post-treatment on lateral tail vein 
blood samples using a OneTouch glucometer 
(Lifescan Scotland Ltd) throughout the treat-
ment period. 
 
Behavioral assessment of early diabetic 
neuropathy 
Both thermal hyperalgesia and cold allo-
dynia were studied after one and two-week 
post-treatment. Thermal hyperalgesia was 
studied by measuring paw and tail withdrawal 
latency (sec) by hot plate and tail immersion 
test at 49 ± 0.5 oC. Shortening of the paw and 
tail withdrawal latency indicates thermal hy-
peralgesia. Cold allodynia was studied by 
measuring tail withdrawal latency (sec) by 
dipping the tail in the water at a cold temp (10 
± 0.5 °C), which is usually innocuous.  
 
Determination of the serum biochemical 
parameters 
Serum urea, uric acid, creatinine, triglyc-
erides, and total cholesterol levels were meas-
ured by using the standard commercially 
available kits and as per the instructions of 
manufacturer’s. 
 
Determination of tissue antioxidant status 
At the end of the experiment, the sciatic 
nerve and kidney were isolated and washed 
with ice-cold saline. Then homogenate was 
made and used for determination of MDA, an 
end product of lipid peroxidation (Mihara and 
Uchiyama, 1978), reduced glutathione (GSH) 
(Ellman, 1959), and superoxide dismutase 
(SOD) (Misra and Fridovich, 1972). 
 
Histopathological examinations 
The part of the isolated kidney and sciatic 
nerves were fixed in 10 % formalin. The par-
affin embedded sections of 5 μm thickness 
were cut and stained with hematoxylin and 
eosin (H&E). The kidney histological sec-
tions were examined by light microscopy at 
20x, whereas the sciatic nerve sections were 
examined by oil immersion lens (100x). 
Quantitative estimation of urinary space, glo-
merular tuft area (GA) of kidney sections, 
mean axonal, and fiber diameter in sciatic 
nerve sections was determined by using Im-
ageJ software. The glomerular volume (GV) 
was calculated by converting GA to GV by 
applying a spherical approximation formula 
(GV = 1.2545 (GA)1.5) (Gopala and Greg, 
2007). For each parameter, six images from 
six different samples of each study group 
were analyzed. Five non-overlapping fields 
from each image were captured. Five differ-
ent readings from every captured photo were 
counted, and the mean was calculated for each 
image.  
 
Data analysis and statistics 
One-way analysis of variance (ANOVA) 
followed by post-hoc Tukey’s HSD test was 
performed to conduct statistical analysis. All 
values were expressed as means ± SEM. Dif-
ferences were considered significant when *P 
< 0.05 and highly significant when **P < 
0.01. 
 
RESULTS 
Preliminary phytochemical analysis and 
LC-MS characterization of CHFG  
Preliminary phytochemical estimation re-
vealed the presence of alkaloids, flavonoids, 
glycosides, phenolics, and saponins. CHFG 
was characterized by LC-MS, and phytocon-
stituents in the extract were identified by the 
compound library. The list of the compounds 
detected is given in Table 1.  
 
Acute oral toxicity study  
In the present study, none of the rats 
showed visible signs of toxicity after treat-
ment with a single oral dose of 2000 mg/kg of 
CHFG extract. Observations twice daily for 
two weeks also did not reveal any drug-re-
lated toxicity. 
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Table 1: The list of the compounds detected from 
the CHFG by LC-MS 
 
 
 
Effect on oral glucose tolerance test and  
selection of dose 
Hypoglycemic activity of CHFG 200, 
CHFG 400, and CHFG 600 of extract and Met 
250 on glucose tolerance was examined in 
glucose loaded rats (Figure 1). Rats treated 
with CHFG 200, CHFG 400, and CHFG 600 
and Met 250 mg/kg significantly (P	< 0.01) 
lower the FBG level in comparison to the nor-
mal control group. The dose-dependent de-
crease in FBG level was observed in CHFG 
200 and CHFG 400. However, CHFG 600 
fails to show a significant dose-dependent ac-
tivity as compared to its lower dose of CHFG 
400. Hence, for the final study in STZ induced 
diabetic rats, two doses, CHFG 200 and 
CHFG 400, were selected. 
 
Figure 1: Effect of single-dose treatment on oral glu-
cose tolerance in normoglycemic rats. All values were 
expressed as Mean + SEM, (n = 6); *P < 0.05, **P < 
0.01 as compared to normal control group. 
Effect on fasting blood glucose level 
The fasting blood glucose levels for both 
single and repeated dose treatment with Met 
250, CHFG 200, and CHFG 400 were meas-
ured in STZ-induced diabetic rats (Figure 2a 
and 2b). Fasting blood glucose level of single-
dose treatment was fall significantly (P < 
0.01) after 4 and 6 hours post-treatment in 
Met 250, CHFG 200, and CHFG 400 group as 
compared to the diabetic control group (Fig-
ure 2a). There were 41.27 %, 17.88 %, and 
29.13 % fall in blood glucose level after 4 
hours post-treatment in Met 250, CHFG 200, 
and CHFG 400 groups, respectively, as com-
pared to the diabetic control group. There was 
50.53 %, 21.64 %, and 34.98 % fall in blood 
glucose level after 6 hours post-treatment in 
Met 250, CHFG 200, and CHFG 400 groups, 
respectively, as compared to the diabetic con-
trol group. 
  
 
 
Figure 2: a) Effect of single-dose treatment on blood 
glucose level in STZ-induced diabetic rats. b) Effect of 
repeated-dose treatment on blood glucose level in STZ-
induced diabetic rats. OWPT: One Week Post Treat-
ment, © = observation recorded three weeks after in-
duction of diabetes, TWPT: Two Weeks Post Treat-
ment, ® = observation recorded four weeks after induc-
tion of diabetes, All values were expressed as Mean + 
SEM, (n = 6); #P < 0.01, as compared to normal control 
group; *P < 0.05, **P < 0.01 as compared to diabetic 
control group. 
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Repeated dose treatment with Met 250, 
CHFG 200, and CHFG 400 showed signifi-
cant (P < 0.01) fall in blood glucose level 
compared to the diabetic control group (Fig-
ure 2b). There was 21.64 %, 11.12 %, and 
16.64 % fall in fasting blood glucose level af-
ter one-week post-treatment (OWPT) in Met 
250, CHFG 200, and CHFG 400 groups re-
spectively as compared to the diabetic control 
group. There were 41.29 %, 20.58 %, and 
26.21 % fall in fasting blood glucose level af-
ter two weeks post-treatment (TWPT) in Met 
250, CHFG 200, and CHFG 400 groups re-
spectively as compared to the diabetic control 
group.  
 
Effect on thermal hyperalgesia 
The pain threshold was significantly re-
duced in diabetic rats as compared with the 
normal control group (Figure 3a and 3b). 
Treatment of diabetic rats with Met 250, 
CHFG 200, and CHFG 400 revealed an in-
crease in pain threshold after OWPT and 
TWPT as compared to the diabetic control 
group. 
 
Effect on cold allodynia 
Tail flick latency at 10 °C was signifi-
cantly (P < 0.01) lower in diabetic rats after 
two weeks of diabetes as compared with the 
normal control group (Figure 4). Treatment of 
diabetic rats with CHFG 400 showed statisti-
cally significant (P < 0.01) increase in pain 
threshold after OWPT and TWPT as com-
pared to the diabetic control group. Although 
Met 250 and CHFG 200 fails to show a statis-
tically significant difference in OWPT but 
showed a statistically significant increase in 
pain threshold in Met 250 (P < 0.05), CHFG 
200 (P < 0.01) after TWPT as compared to the 
diabetic control group. 
 
  
 
 
Figure 3: a) Effect of repeated-dose treatment on paw 
withdrawal latency (PWL) using a hot plate test at 49 °C 
in STZ-induced diabetic rats. b) Effect of repeated-dose 
treatment on tail-flick latency (TFL) using water immer-
sion test at 49 °C in STZ-induced diabetic rats. OWPT: 
One Week Post Treatment, © = observation recorded 
three weeks after induction of diabetes, TWPT: Two 
Weeks Post Treatment, ® = observation recorded four 
weeks after induction of diabetes, All values were ex-
pressed as Mean + SEM, (n = 6); # P < 0.01, as com-
pared to normal control group; *P < 0.05, **P < 0.01 as 
compared to diabetic control group. 
 
Figure 4: Effect of repeated-dose treatment on cold al-
lodynia using water immersion test at 10 °C in STZ-in-
duced diabetic rats. OWPT: One Week Post Treatment, 
© = observation recorded three weeks after induction of 
diabetes, TWPT: Two Weeks Post Treatment, ® = ob-
servation recorded four weeks after induction of diabe-
tes, All values were expressed as Mean + SEM, (n = 6); 
#P < 0.01, as compared to normal control group; *P < 
0.05, **P < 0.01 as compared to diabetic control group.  
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Effect on body weight, kidney weight and 
kidney weight to body weight ratio 
A statistically significant (P < 0.01) de-
crease in body weight in the diabetic control 
group was observed as compared to the nor-
mal control group. OWPT treatment with 
CHFG 400 showed a statistically significant 
(P < 0.01) increase in the body weight as com-
pared to the diabetic control group. Consider-
able increase in the body weight after TWPT 
with Met 250 (P < 0.01), CHFG 200 (P < 
0.05), and CHFG 400 (P < 0.01) was observed 
against the diabetic control group (Figure 5a). 
Moreover, there was a remarkable elevation 
in kidney weights to body weight ratio in the 
diabetic control group. In contrast, kidney 
weight to body weight ratio was significantly 
(P < 0.01) lower in the TWPT with Met 250, 
CHFG 200 and CHFG 400 treatment group as 
compared to the diabetic control group (Fig-
ure 5b). 
 
Effect on biochemical parameters 
Table 2 presents the study on serum urea, 
uric acid, creatinine, triglycerides, and total 
cholesterol level. In comparison to the normal 
control group, STZ treated diabetic rats 
showed a significant (P < 0.01) increase in se-
rum urea, uric acid, creatinine, triglyceride, 
and total cholesterol level. Met 250, CHFG 
200, and CHFG 400 showed a significant (P 
< 0.01) decrease in serum urea level as com-
pared to the diabetic control group. TWPT 
with Met 250 and CHFG 400 significantly (P 
< 0.01) reduced serum uric acid, creatinine, 
triglyceride, and total cholesterol level as 
compared to the diabetic control group. 
TWPT with CHFG 200 significantly (P < 
0.05) decreased serum triglyceride, but it fails 
to show a significant change in serum creati-
nine and total cholesterol level as compared 
to the diabetic control group. 
 
  
 
  
Figure 5: a) Effect of repeated-dose treatment on body 
weight in STZ-induced diabetic rats. b) Effect of re-
peated-dose treatment on kidney weight to body weight 
ratio in STZ-induced diabetic rats. OWPT: One Week 
Post Treatment, © = observation recorded three weeks 
after induction of diabetes, TWPT: Two Weeks Post 
Treatment, ® = observation recorded four weeks after 
induction of diabetes, All values were expressed as 
Mean + SEM, (n = 6); #P < 0.01, as compared to normal 
control group; *P < 0.05, **P < 0.01 as compared to di-
abetic control group. 
 
Effect on serum antioxidant status 
Significant (P < 0.01) increase in MDA 
level (3.08 fold in sciatic nerve and 1.79 fold 
in kidney tissue), decrease in GSH (1.73 fold 
in sciatic nerve and 1.96 fold in kidney tissue) 
and decrease in SOD (1.66 fold in sciatic 
nerve and 1.85 fold in kidney tissue) were ob-
served in diabetic control rats as compared to 
normal control rats (Table 3).  
Administration of Met 250 for two weeks 
significantly (P < 0.01) decreases MDA (2.02 
fold in sciatic nerve and 1.44 fold in kidney 
tissue), increases GSH (1.47 fold in sciatic 
nerve and 1.46 fold in kidney tissue) and in-
creases SOD (1.36 fold in sciatic nerve and 
1.53 fold in kidney tissue) as compared to 
their level in respective tissues in diabetic 
control group (Table 3). 
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Table 2: Effect of repeated-dose treatment on serum biochemical parameters in STZ-induced diabetic 
rats 
® = observation recorded two-week post-treatment and four weeks after induction of diabetes. All values were 
expressed as Mean + SEM, (n = 6); #P < 0.01, as compared to normal control group; *P < 0.05, **P < 0.01 as 
compared to diabetic control group. 
 
 
Table 3: Effect of repeated-dose treatment on antioxidant activity of sciatic nerve and kidney tissue in 
STZ-induced diabetic rats 
 
® = observation recorded two-week post-treatment and four weeks after induction of diabetes. All values were 
expressed as Mean + SEM, (n = 6); #P < 0.01, as compared to normal control group; *P < 0.05, **P < 0.01 as 
compared to diabetic control group. 
 
 
TWPT with CHFG 200 showed a signifi-
cant decrease in MDA level (1.58 fold in the 
sciatic nerve and 1.27 fold in kidney tissue) as 
compared to their level in respective tissues in 
the diabetic control group. Although TWPT 
with CHFG 200 increases GSH level by 1.21 
fold in the sciatic nerve and 1.27 fold in kid-
ney tissue but this improvement was found to 
be non-significant as compared to their level 
in respective tissues in the diabetic control 
group. Also, CHFG 200 showed a significant 
increase in SOD by 1.25 fold in sciatic nerve 
(P < 0.01) and 1.28 fold in kidney tissue (P-
ns) as compared to their level in respective tis-
sues in the diabetic control group (Table 3). 
Whereas treatment with CHFG 400 for two 
weeks significantly (P < 0.01) decreases 
MDA (2.43 fold in sciatic nerve and 1.66 fold 
in kidney tissue), increases (P < 0.01) GSH 
(1.58 fold in sciatic nerve and 1.76 fold in kid-
ney tissue) and increases (P < 0.01) SOD 
(1.41 fold in sciatic nerve and 1.59 fold in kid-
ney tissue) as compared to their level in re-
spective tissues in diabetic control group (Ta-
ble 3). 
 
Effect of CHFG on histopathological  
analysis of kidney and sciatic nerve 
Figure 6 showed the effect of CHFG on 
glomerular morphology. The histopathologi-
cal study revealed normal glomeruli in the 
normal control group (Figure 6a). The kidney 
sections of diabetic rats showed significant (P 
< 0.01) increase in glomerular volume and 
urinary space (P < 0.01), and presence of glo-
merular capillary congestion with hemor-
rhage as compared to kidney section of the 
normal control group (Figure 6b, f, and g). 
The TWPT with Met 250 and CHFG 400 
showed statistically significant (P < 0.01) de-
crease in glomerular volume and urinary 
space (P < 0.05 in Met 250, and P < 0.01 in 
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CHFG 400) and absence of capillaries con-
gestion without hemorrhage (Figure 6c, e, f, 
and g). Whereas, the TWPT with CHFG 200 
showed statistically insignificant changes in 
glomerular volume and urinary space as com-
pared to the diabetic control group. Also, it 
showed the evidence of hemorrhage with the 
minor blood-filled area (Figure 6d, f, and g).
 
 
   
 
 
  
 
  
Figure 6: Light microscopic representative images of kidney tissues (HE stained sections, 20X, Scale bar 50 μm). 
a) Normal control, showing normal urinary space, and glomerular volume (arrowhead). b) Diabetic control, showing 
an increase in urinary space (arrowhead), increased in glomerular tuft area (arrowhead) and the presence of capil-
laries congestion with hemorrhage (arrow) as compared to normal control. c) STZ + Met 250 showed a decrease 
in urinary space (arrowhead), decreased in glomerular tuft area (arrowhead), and the absence of capillaries con-
gestion without hemorrhage. d) STZ + CHFG 200 showed an insignificant decrease in urinary space (arrowhead), 
decreased in glomerular tuft area (arrowhead), and evidence of hemorrhage (arrow). e) STZ + CHFG 400 showed 
a decrease in urinary space (arrowhead), decreased in glomerular tuft area (arrowhead), and absence of capillaries 
congestion with no evidence of hemorrhage. f) Effect of repeated-dose treatment on the glomerular volume of 
kidney tissue. g) Effect of repeated-dose treatment on urinary space of kidney tissue. TWPT: Two Weeks Post 
Treatment, ® = observation recorded four weeks after induction of diabetes. All values were expressed as Mean + 
SEM, (n = 6); #P < 0.01, as compared to the normal control group; *P < 0.05, **P < 0.01 as compared to the diabetic 
control group.
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Histopathological study of the normal 
control group showed normal sciatic nerve ar-
chitecture (Figure 7a). Axonal atrophy with 
significant (P < 0.01) decrease in mean ax-
onal, and fiber diameter was seen in the sci-
atic nerve section of the diabetic control 
group as compared to the normal control 
group (Figure 7b, f, and g). The TWPT with 
Met 250 and CHFG 400 showed statistically 
significant (P < 0.01) preservation of mean 
axonal and fiber diameter in the sciatic nerve 
section of the treatment group as compared to 
the diabetic control group (Figure 7c, e, f, and 
g). Whereas the TWPT with CHFG 200 
showed the statistically insignificant change 
in mean axonal and fiber diameter in the sci-
atic nerve section as compared to the diabetic 
control group (Figure 7d, 7f, and 7g).
 
     
 
    
  
Figure 7: Light microscopic representative images of sciatic nerve tissue (HE stained sections, 100X, immersion 
oil, Scale bar 5 μm). a) Normal control showing normal histological features of axonal fiber (arrow). b) Diabetic 
control showing axonal atrophy (arrow). c) STZ + Met 250 showing less axonal atrophy as compared to the diabetic 
control group. d) STZ + CHFG 200 showed axonal atrophy (arrow). e) STZ + CHFG 400, showing less axonal 
atrophy as compared to the diabetic control group. f) Effect of repeated-dose treatment on the mean axonal diam-
eter of sciatic nerve tissue. g) Effect of repeated-dose treatment on the mean fiber diameter of sciatic nerve tissue. 
TWPT: Two Weeks Post Treatment, ® = observation recorded four weeks after induction of diabetes. All values 
were expressed as Mean + SEM, (n = 6); #P < 0.01, as compared to the normal control group; *P < 0.05, **P < 
0.01 as compared to the diabetic control group.
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DISCUSSION 
Diabetes is one of the major endocrine 
disorders that leads to impairment of renal 
and neural microvasculature (UK Prospective 
Diabetes Study (UKPDS), 1991; Yagihashi et 
al., 1992). Hyperglycemia-induced oxidative 
stress is a crucial element initiating diabetic 
microvascular complications (Jha et al., 
2016). Oxidative stress in diabetes is the re-
sult of a series of pathological events that 
leads to an imbalance between the pro-oxi-
dant levels and counteracting antioxidant de-
fense mechanisms, consequently both kidney 
and nerves which are an essential part of the 
body are susceptible to hyperglycemia-in-
duced oxidative damage (Asieh and Moham-
mad, 2013; Jha et al., 2016). 
The antioxidant effects on the diabetic 
kidney (Lee et al., 2008) and nerves (Salma et 
al., 2017) disorders were positively correlated 
with medicinal herbs supplementation. Alt-
hough our previous in vitro study showed sig-
nificant antidiabetic and antioxidant activity 
(Abusufyan et al., 2018) to CHFG, no study 
was conducted to observe the effects of 
CHFG in diabetic renal and neural complica-
tions. We have planned our investigation to 
evaluate the influence of CHFG against dia-
betes-induced renal and neural complications. 
In the current study, diabetic rats were af-
fected by their behavioral and biochemical 
parameters. Diabetic rats showed severe hy-
perglycemia, an increase in plasma urea, uric 
acid, creatinine, triglyceride, and total choles-
terol level. In addition, diabetic rats revealed 
altered behavioral parameters such as thermal 
hyperalgesia and cold allodynia, decreased 
body weight, and increased kidney weight to 
body weight ratio beside compromised sciatic 
nerve and kidney antioxidant status. Previous 
studies have shown that hyperglycemia can 
induce similar early renal and neural compli-
cations in diabetic rats (Bhaskar et al., 2014; 
Morsy et al., 2014). The administration of 
CHFG to the STZ induced diabetic rats im-
proved the parameters discussed above. This 
protective effect of CHFG has not been re-
ported earlier. 
The CHFG showed a significant decrease 
in blood glucose levels at 200 mg/kg and 400 
mg/kg body weight in STZ induced diabetic 
rats both in a single dose and in one and two 
weeks repeated dose treatment. Our previous 
study showed in vitro inhibition of α-gluco-
sidase and α-amylase enzymes by CHFG ex-
tract (Abusufyan et al., 2018). α-glucosidase 
and α-amylase are two important enzymes 
that convert starch to more simple sugars. 
Therefore, the inhibition of these enzymes re-
duces the rate of absorption of glucose that 
helps in controlling the postprandial rise in 
the blood glucose levels. 
Neuropathic pain associated with diabetes 
is characterized by two important sensory 
symptoms such as hyperalgesia i.e. an in-
creased response to painful stimuli, and allo-
dynia, i.e. pain in response to a non-painful 
stimulus (Bianchi et al., 2012). In the present 
study, diabetic rats showed a significant in-
crease in paw and tail withdrawal latency at 
49 °C (Thermal hyperalgesia) and tail with-
drawal latency at 10 °C (Cold allodynia) as 
compared to the normal control group. Simi-
lar observations were also reported in earlier 
findings (Arun et al., 2008). Administration 
of Met 250 and CHFG 400 resulted in a con-
sequent decrease in both thermal hyperalgesia 
and cold allodynia, compared to diabetic rats. 
Free radical-induced oxidative stress has been 
implicated to play an important role in the 
pathogenesis of diabetic neuropathy (Nasiry 
et al., 2017). In the present study, there was a 
significant increase in sciatic nerve MDA 
level and decrease in SOD and GSH level in 
diabetic rats, which is indicative of impaired 
oxidative balance in the sciatic nerve of dia-
betic rats. Treatment with Met 250 and CHFG 
200 and CHFG 400 reduces oxidative stress 
parameters of the sciatic nerve. The anti-noci-
ceptive effect of CHFG may be attributed to 
its neuroprotective effect, which might be due 
to its antioxidant activity.  
In the present investigation, the diabetic 
rats showed a significant decrease in body 
weight and increase in kidney weight to body 
weight ratio. Similar results have been found 
by Manikanta and Rema (2017) in STZ 
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treated four weeks of diabetic rats at a dose of 
55 mg/kg, i.p. The significant decline of body 
weight could be due to hyperglycemia, hypo-
insulinemia, loss of tissue proteins, and in-
creased muscle wasting (Cheng and Liang, 
2013; Zafar and Naqvi, 2010). In our experi-
mental study, the administration of CHFG to 
diabetic rats significantly improved the body 
weight that indicates the inhibition of loss of 
protein and muscle tissue damage caused by 
hyperglycemia. CHFG also improved kidney 
weight to body weight ratio, which could be 
attributed to its protective effect against oxi-
dative stress induced cell injury in the renal 
tissues. 
Changes in kidney weights to body weight 
ratio in diabetic rats were also associated with 
an increase in serum urea, uric acid, and cre-
atinine, which is considered as the marker of 
kidney impairment (Karahan et al., 2005; 
Soussi et al., 2018). Catabolism of protein and 
nucleic acid due to hyperglycemia result in 
the formation of non-protein nitrogenous 
compounds such as urea, uric acid, and creat-
inine in diabetic rats (Yassin and Mwafy, 
2007). In the present study, the diabetic rats 
showed an increase in the serum levels of 
urea, uric acid, and creatinine. The treatment 
with Met 250, CHFG 400, significantly atten-
uated the hyperglycemia-induced kidney im-
pairment indicated above. Kidney function 
impairment could be attributed to oxidative 
damage caused by hyperglycemia (Jha et al., 
2016; Soussi et al., 2018). Our experimental 
results revealed a state of oxidative stress in 
diabetic rats by the significant elevation in 
kidney MDA, decreased in SOD and GSH. 
Treatment with Met 250 and CHFG 400 re-
duces kidney MDA levels and increases the 
level of SOD and MDA. 
The previous study revealed that diabetic 
patients with high cholesterol and triglyceride 
levels are at high risk of nephropathy and pe-
ripheral neuropathy (Aguiar et al., 2015; 
Wheeler and Bernard, 1994). In the present 
study, there was a significant increase in se-
rum triglyceride and total cholesterol levels in 
diabetic rats as compared to normal control 
rats. Treatment with Met 250 and CHFG 400 
reduces serum triglyceride and total choles-
terol levels. This hypolipidemic activity of 
CHFG might also improve blood supply to 
the kidney and peripheral nerve, and in turn, 
it reduces its ischemic degeneration. The bio-
chemical parameters were correlated with re-
nal and neural histological studies. The histo-
pathological observation in the kidney tissue 
of diabetic control rats showed an increase in 
glomerular volume, urinary space, and capil-
lary congestion with hemorrhage. The previ-
ous study conducted by Malatiali et al. 
(2008), Kartiawati et al. (2017), and Krishan 
et al. (2017) showed a similar change in typi-
cal architecture of kidney tissue of diabetic 
rats. Our study also reports that CHFG 400 
showed marked improvement in the histolog-
ical sections with a decrease in urinary space 
and glomeruli volume. Morphological assess-
ments of sciatic nerve showed a decline in the 
mean nerve fiber and axonal fiber diameter in 
the sciatic nerve tissue in diabetic control rats. 
The study conducted by Sameni et al. (1994) 
showed similar changes in the sciatic nerve of 
diabetic rats. The administration of CHFG 
400 markedly reduced these changes in the 
sciatic nerve tissues. The findings of kidney 
and sciatic nerves histopathological study 
were in line with the biochemical parameters 
that revealed the beneficial role of CHFG in 
the treatment of diabetic renal and neural 
complications. 
Our previous correlation study of differ-
ent FG leaf extracts showed a moderately pos-
itive correlation between total flavonoids con-
tent and in vitro antidiabetic activity and a 
strong positive relationship between phenolic 
content, and its in vitro antioxidant activity 
(Abusufyan et al., 2018). Also, quantitative 
phytochemical estimation of CHFG showed 
the presence of 352.49 mg/g quercetin equiv-
alents (QE) of total flavonoids and 27.43 
mg/g gallic acid equivalent (GAE) of total 
phenolic content. Characterization of CHFG 
by LC-MS has detected diverse phytoconstit-
uents (Table 1), out of which 3-Methoxycate-
chol and p-Cymene were reported in literature 
for their antioxidant activity (Loo et al., 2008; 
EXCLI Journal 2020;19:33-47 – ISSN 1611-2156 
Received: May 14, 2019, accepted: December 19, 2019, published: January 03, 2020 
 
 
45 
de Oliveira et al., 2015) and Anethole was re-
ported for its hypoglycemic, antioxidant and 
neuroprotective activities (Sheikh et al., 2015; 
Bing et al., 2018). Dual antidiabetic and anti-
oxidant activity of CHFG phytoconstituents 
might be responsible for their protective ef-
fect against early diabetic renal and neural 
damage in STZ rats.  
 
CONCLUSION 
Our findings revealed a protective effect 
of CHFG against STZ-induced oxidative 
damage, alteration of biochemical parame-
ters, and histopathology. Favorable health ef-
fects of FG leaf extracts have been docu-
mented and can partially explain the observed 
reno-protective and neuroprotective effects of 
CHFG. The current investigation, therefore, 
provides evidences that support the beneficial 
effect of CHFG against STZ-induced oxida-
tive damage on the renal and neural system. 
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